Severino Beatrice, Corvino Angela, Fiorino Ferdinando, Frecentese Francesco, Perissutti Elisa, Caliendo Giuseppe, Santagada Vincenzo, Magli Elisa, Molinaro Pasquale, Pignataro Giuseppe, Annunziato Lucio, Antunes Natalícia J, Rojas-Moscoso Julio, de Freitas Noedi L, Mendes Gustavo D, De Nucci Gilberto
Department of Pharmacy, School of Medicine, University of Naples Federico II, Naples, Italy.
Department of Neuroscience, Reproductive and Odontostomatological Sciences, School of Medicine, University of Naples Federico II, Naples, Italy.
Front Pharmacol. 2019 Apr 25;10:432. doi: 10.3389/fphar.2019.00432. eCollection 2019.
Neurounina-1 [chemical name: 7-nitro-5-phenyl-1-(pyrrolidin-1-ylmethyl)-1H-benzo[e][1,4]diazepin-2(3H)-one] is a new compound provided with relevant neuroprotective effect during stroke and in neonatal hypoxia by increasing the Na/Ca exchanger (NCX) isoforms NCX1 and NCX2 activity. This study shows for the first time, the development and validation of a sensitive and selective method for analysis of neurounina-1 in beagle dog plasma by liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The sample preparation consisted of extraction of the analyte and the internal standard (IS) (ropivacaine) from plasma (50 μL) by liquid-liquid extraction using acetonitrile (100 μL). The selected reaction monitoring mode of the positive ion was performed and the precursor to the product ion transitions of m/z 365 > 83 and m/z 275 > 126 were used to measure the derivative of neurounina-1 and ropivacaine. The chromatographic separation was achieved using a Phenomenex C18 Luna (150 mm × 4.6 mm × 5 μm) analytical column with an isocratic mobile phase composed of methanol/acetonitrile/water (50/40/10, v/v/v) + 0.1% formic acid + 1 M ammonium formate. The method was linear over a concentration range of 1-500 ng/mL. The method was applied to evaluate the pharmacokinetics of neurounina-1 after a single intravenous administration of three different doses (0.1 mg/kg, 0.3 mg/kg, and 1 mg/kg) to beagle dogs ( = 5). The mean AUC values were 26.10, 115.81, and 257.28 ngh/mL following intravenous administration of 0.1, 0.3, and 1 mg/kg, respectively. Linear pharmacokinetics was observed up to 1.0 mg/kg. The neurounina-1 was rapidly eliminated, with mean CL values of 46.24, 47.57, and 69.15 L/h, Vd of 130.31, 154.15, and 210.79 L and t of 2.14, 2.54, and 2.04 h after intravenous administration of 0.1, 0.3, and 1 mg/kg, respectively. This new analytical method allows the rapid determination of the neurounina-1, a new developed compound, able to exert a remarkable neuroprotective effect in the low nanomolar range.
神经优宁娜 -1[化学名称:7 - 硝基 -5 - 苯基 -1 -(吡咯烷 -1 - 基甲基)-1H - 苯并[e][1,4]二氮杂卓 -2(3H)- 酮]是一种新化合物,通过提高钠/钙交换体(NCX)亚型NCX1和NCX2的活性,在中风和新生儿缺氧期间具有相关神经保护作用。本研究首次展示了一种通过液相色谱 - 串联质谱(LC - MS/MS)分析比格犬血浆中神经优宁娜 -1的灵敏且选择性方法的开发与验证。样品制备包括通过用乙腈(100 μL)进行液 - 液萃取从血浆(50 μL)中提取分析物和内标(IS)(罗哌卡因)。采用正离子的选择反应监测模式,使用m/z 365 > 83和m/z 275 > 126的前体到产物离子转换来测量神经优宁娜 -1和罗哌卡因的衍生物。使用Phenomenex C18 Luna(150 mm×4.6 mm×5 μm)分析柱,以甲醇/乙腈/水(50/40/10,v/v/v)+ 0.1%甲酸 + 1 M甲酸铵组成的等度流动相实现色谱分离。该方法在1 - 500 ng/mL的浓度范围内呈线性。该方法应用于评估比格犬(n = 5)单次静脉注射三种不同剂量(0.1 mg/kg、0.3 mg/kg和1 mg/kg)后神经优宁娜 -1的药代动力学。静脉注射0.1、0.3和1 mg/kg后,平均AUC值分别为26.10、115.81和257.28 ngh/mL。在高达1.0 mg/kg时观察到线性药代动力学。神经优宁娜 -1被快速消除,静脉注射0.1、0.3和1 mg/kg后,平均CL值分别为46.24、47.57和69.15 L/h,Vd分别为130.31、154.15和210.79 L,t1/2分别为2.14、2.54和2.04 h。这种新的分析方法能够快速测定神经优宁娜 -1,一种新开发的化合物,在低纳摩尔范围内能发挥显著的神经保护作用。